Grant ID RP121035
Awarded On March 29, 2012
Title Development and Pre-clinical Testing of Therapeutic MYCN Vaccine
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization Baylor College of Medicine
Principal Investigator/Program Director Leonid S Metelitsa
Cancer Sites Other
Contracted Amount $1,023,174
Lay Summary

The overall goal of project-3 is to develop a safe and effective immunotherapy of neuroblastoma (NB) by targeting MYCN oncogene with a novel type of cancer vaccine. MYCN is a causative oncogene in MYCN-amplified (MYCN-A) NB, the most deadly type of the disease. MYCN represents a nearly ideal target for immunotherapy since it is highly expressed in the malignant neuroblasts, essential for their survival, and not detectable in normal tissues after birth. We recently reported a new type of oral cancer vaccine that uses type-3 secretion system of Salmonella to translocate tumor-associated antigens into the cytosol of antigen-presenting cells. Our new MYCN vaccine carried by an attenuated Salmone...

Read More